뇌종양 진단 및 치료 시장 : 치료법별, 진단법별, 종양 유형별, 종양 악성도별, 약제 분류별, 투여 경로별, 용도별, 최종 사용자별, 환자 연령층별 예측(2026-2032년)

The Brain Tumor Diagnosis & Therapeutics Market is projected to grow by USD 5.80 billion at a CAGR of 9.66% by 2032.

Brain tumor diagnosis and therapeutics is moving from a morphology-led specialty to an integrated precision neuro-oncology market spanning advanced MRI, PET imaging, stereotactic biopsy, molecular pathology, surgical navigation, radiotherapy planning, systemic therapy, tumor treating fields, and longitudinal monitoring.

The clinical need remains substantial. IARC GLOBOCAN 2022 estimates approximately 321,700 new brain and central nervous system cancer cases and 248,800 deaths worldwide, while U.S. CBTRUS reporting indicates more than 94,000 primary brain and CNS tumors are diagnosed annually when malignant and non-malignant tumors are combined. The 2021 WHO Classification of CNS Tumors accelerated biomarker-driven care by integrating histology with molecular features such as IDH mutation, 1p/19q co-deletion, MGMT promoter methylation, TERT promoter mutation, and H3 K27 alterations.

For diagnostics, therapeutics, and imaging stakeholders, demand is being shaped by earlier detection, surgical precision, response assessment, and therapy selection. Transformative Shifts in the Brain Tumor Care Landscape

The landscape is shifting as brain tumor classification, treatment selection, and clinical trial design become increasingly biomarker-led. Gliomas are no longer managed by histology alone; molecular profiling now influences prognosis, eligibility for targeted therapy, and interpretation of radiographic progression.

In surgery, technologies such as intraoperative MRI, fluorescence-guided resection with 5-ALA, neuronavigation, cortical mapping, and awake craniotomy are helping neurosurgeons maximize safe resection while protecting neurological function. In radiation oncology, stereotactic radiosurgery, hypofractionation, proton therapy, and adaptive planning are enabling more personalized dose delivery.

Therapeutics are also diversifying beyond temozolomide-based regimens. FDA approvals in recent years for targeted agents in BRAF-altered pediatric low-grade glioma and IDH-mutant glioma, along with continued use of tumor treating fields in glioblastoma, show a clear movement toward molecularly segmented care. Competitive organizations are aligning diagnostics, therapeutics, and real-world evidence generation into one integrated value proposition.

Cumulative Impact of Artificial Intelligence on Neuro-Oncology

Artificial intelligence is becoming a cumulative enabler across the brain tumor pathway rather than a single-point technology. In imaging, AI-supported segmentation can help quantify enhancing tumor, edema, necrosis, and treatment-related change on MRI. In pathology, computational tools are being evaluated to support tumor grading, mitotic assessment, methylation-class prediction, and molecular triage.

The strongest near-term value is operational and clinical: faster radiology workflows, more reproducible volumetric assessment, improved radiation treatment planning, earlier identification of recurrence patterns, and more efficient trial screening. AI can also support radiomics-based risk stratification, although clinical adoption requires validation across scanners, institutions, patient demographics, and tumor subtypes.

Regulators increasingly emphasize transparency, performance monitoring, cybersecurity, and human oversight for AI-enabled medical devices. For industry leaders, success will depend on clinically validated algorithms, interoperability with PACS, EHR, pathology, and treatment planning systems, and evidence showing that AI improves decision quality without adding workflow burden.

Key Regional Insights Across Global Brain Tumor Markets

North America remains a leading region for brain tumor diagnosis and therapeutics because of dense academic cancer center networks, high MRI and neurosurgical capacity, FDA-cleared technologies, NCCN-guided care pathways, and active clinical trial enrollment. The United States anchors innovation through federal research funding, national cancer programs, university hospitals, and venture-backed medtech and biotech ecosystems, while Canada contributes through publicly funded cancer systems and collaborative neuro-oncology research.

Europe is shaped by EMA oversight, EANO guidance, national health technology assessment, and strong reference centers in the United Kingdom, Germany, France, Italy, and Spain. The region is highly influential in evidence standards, reimbursement decisions, and multinational trials. Asia-Pacific is the most demographically significant opportunity, with Japan, South Korea, Australia, China, and India expanding advanced imaging, neurosurgery, radiotherapy, and molecular testing capacity at different speeds.

Latin America, led by Brazil and Mexico, shows growing demand but uneven access to MRI, pathology, radiotherapy, and innovative oncology drugs. The Middle East is strengthening tertiary care through GCC investments in oncology hospitals and digital health infrastructure. Africa faces the greatest access constraints, including shortages of neurosurgeons, radiotherapy units, neuropathology, and molecular diagnostics, making scalable capacity-building central to market development.

Key Group Insights for Strategic Market Prioritization

ASEAN presents a mixed-access environment where Singapore, Thailand, and Malaysia offer stronger tertiary neuro-oncology capacity, while larger markets such as Indonesia, Vietnam, and the Philippines require broader investment in imaging, pathology, and specialist training. Demand is rising as health systems expand cancer coverage and private hospital networks adopt advanced MRI and radiotherapy.

The GCC is prioritizing oncology infrastructure, medical tourism, and digital transformation, making it attractive for premium diagnostics, stereotactic radiation partnerships, and AI-enabled hospital workflows. The European Union offers a large, regulated market where centralized evidence standards, medical device regulation, and cross-border cancer initiatives support harmonized adoption, although reimbursement remains country-specific.

BRICS countries represent scale, epidemiologic need, and manufacturing potential, but adoption varies widely by reimbursement, regulatory maturity, and specialist availability. G7 markets remain the core engines for brain tumor innovation, clinical trials, and premium-pricing evidence. NATO countries are relevant through resilient medical supply chains, cybersecurity standards, and overlap with advanced North American and European healthcare systems that procure high-acuity oncology technologies.

Key Country Insights Shaping Brain Tumor Market Opportunity

The United States is the largest innovation hub for brain tumor diagnostics and therapeutics, supported by FDA pathways, NCI-designated cancer centers, CBTRUS epidemiologic infrastructure, and strong clinical trial activity. Canada complements this with universal healthcare, provincial cancer agencies, and academic research networks, while Mexico and Brazil present expanding demand but face access gaps in molecular testing, radiotherapy, and high-cost therapies.

In Europe, the United Kingdom combines NHS-led pathways with genomics initiatives; Germany offers strong hospital infrastructure, imaging access, and medical technology adoption; France is influential in oncology research and reimbursement evaluation; Italy and Spain maintain major neuro-oncology centers despite regional access variation; and Russia has domestic oncology capacity but faces constraints linked to technology access and international collaboration.

In Asia-Pacific, China is rapidly expanding oncology infrastructure, domestic biopharma innovation, and clinical trial capacity. India offers high patient volume and growing private-sector neuro-oncology capability but has affordability constraints. Japan, South Korea, and Australia are advanced markets with strong imaging, surgery, regulatory systems, and research participation, making them important launch and evidence-generation countries.

Actionable Recommendations for Industry Leaders

Industry leaders should build integrated diagnostic-to-treatment pathways that connect MRI, neuropathology, molecular testing, surgical planning, radiotherapy, systemic therapy, and follow-up monitoring. Biomarker access should be treated as a commercial priority because IDH, BRAF, MGMT, 1p/19q, NTRK, and other markers increasingly influence diagnosis, prognosis, and therapy selection.

Organizations should generate region-specific evidence, including survival, functional outcomes, workflow efficiency, cost-effectiveness, and real-world utilization. AI developers must design for interoperability, explainability, bias monitoring, and post-market performance surveillance. Therapeutics developers should pair targeted therapies with companion or complementary diagnostics and prioritize adaptive trial designs for rare molecular subtypes.

Market expansion should balance premium innovation with access models, including hub-and-spoke pathology networks, cloud-supported imaging review, training partnerships, and tiered pricing strategies in emerging markets.

Research Methodology and Evidence Base

This executive summary is based on a structured secondary research methodology using publicly available and authoritative sources, including WHO and IARC GLOBOCAN cancer statistics, CBTRUS epidemiology, FDA and EMA regulatory information, NCCN and EANO clinical guidance, NIH and NCI resources, clinical trial registries, peer-reviewed medical literature, and publicly disclosed institutional information.

Insights were triangulated across epidemiology, regulatory activity, clinical adoption, reimbursement signals, technology availability, and regional healthcare capacity. Emphasis was placed on verified facts, established clinical standards, and observable market shifts rather than unsupported market-size claims. Conclusion: Precision Neuro-Oncology Defines the Next Growth Phase

Brain tumor diagnosis and therapeutics is entering a precision-driven era defined by molecular classification, advanced imaging, targeted treatment, AI-enabled workflow optimization, and evidence-based access strategies. The burden of brain and CNS tumors remains high, and outcomes for aggressive tumors such as glioblastoma continue to create urgent demand for innovation.

The most successful organizations will not compete on single products alone. They will connect diagnostics, therapeutics, data, and care delivery into validated pathways that improve survival, preserve neurological function, and reduce unwarranted variation across regions. As neuro-oncology becomes more integrated, organizations that combine clinical credibility with scalable access models will be best positioned for sustainable growth.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Brain Tumor Diagnosis & Therapeutics Market, by Treatment Type

• 7.1. Chemotherapy
• 7.2. Immunotherapy
  • 7.2.1. CART-T cell Therapy
  • 7.2.2. Vaccine Therapy
• 7.3. Radiation Therapy
  • 7.3.1. External Beam Radiation Therapy
  • 7.3.2. Stereotactic Radiosurgery
  • 7.3.3. Proton Therapy
• 7.4. Surgery
  • 7.4.1. Open Resection
  • 7.4.2. Minimally Invasive Surgery
• 7.5. Targeted Therapy
• 7.6. Supportive Care

8. Brain Tumor Diagnosis & Therapeutics Market, by Diagnostic Modality

• 8.1. Imaging
  • 8.1.1. Magnetic Resonance Imaging (MRI)
  • 8.1.2. Computed Tomography (CT) Scan
  • 8.1.3. Positron Emission Tomography (PET)
• 8.2. Tissue Diagnosis
  • 8.2.1. Biopsy
  • 8.2.2. Histopathology
• 8.3. Molecular Diagnostics
  • 8.3.1. Polymerase Chain Reaction (PCR)
  • 8.3.2. Fluorescence In Situ Hybridization (FISH)
  • 8.3.3. Next-Generation Sequencing (NGS)
• 8.4. Neurological Assessment

9. Brain Tumor Diagnosis & Therapeutics Market, by Tumor Type

• 9.1. Primary Brain Tumors
  • 9.1.1. Benign
    • 9.1.1.1. Chordomas
    • 9.1.1.2. Glomus Jugulare
    • 9.1.1.3. Meningiomas
    • 9.1.1.4. Pituitary Adenomas
  • 9.1.2. Malignant
    • 9.1.2.1. Astrocytomas
    • 9.1.2.2. Medulloblastomas
    • 9.1.2.3. Glioblastomas multiforme
• 9.2. Secondary Brain Tumors

10. Brain Tumor Diagnosis & Therapeutics Market, by Tumor Grade Type

• 10.1. Grade IV
• 10.2. Grade III
• 10.3. Grade II
• 10.4. Grade I

11. Brain Tumor Diagnosis & Therapeutics Market, by Drug Class

• 11.1. Alkylating Agents
• 11.2. Antimetabolites
• 11.3. Kinase Inhibitors
• 11.4. Angiogenesis Inhibitors

12. Brain Tumor Diagnosis & Therapeutics Market, by Route Of Administration

• 12.1. Oral
• 12.2. Intravenous
• 12.3. Intrathecal

13. Brain Tumor Diagnosis & Therapeutics Market, by Application

• 13.1. Tumor Localization
• 13.2. Initial Detection
• 13.3. Differential Diagnosis
• 13.4. Therapeutic Planning
• 13.5. Long-Term Management & Monitoring

14. Brain Tumor Diagnosis & Therapeutics Market, by End User

• 14.1. Hospitals
• 14.2. Specialty Clinics
• 14.3. Ambulatory Surgical Centers
• 14.4. Academic & Research Institutes

15. Brain Tumor Diagnosis & Therapeutics Market, by Patient Age Group

• 15.1. Pediatric
• 15.2. Adult
• 15.3. Geriatric

16. Brain Tumor Diagnosis & Therapeutics Market, by Region

• 16.1. Asia-Pacific
• 16.2. North America
• 16.3. Latin America
• 16.4. Europe
• 16.5. Middle East
• 16.6. Africa

17. Brain Tumor Diagnosis & Therapeutics Market, by Group

• 17.1. ASEAN
• 17.2. GCC
• 17.3. European Union
• 17.4. BRICS
• 17.5. G7
• 17.6. NATO

18. Brain Tumor Diagnosis & Therapeutics Market, by Country

• 18.1. United States
• 18.2. Canada
• 18.3. Mexico
• 18.4. Brazil
• 18.5. United Kingdom
• 18.6. Germany
• 18.7. France
• 18.8. Russia
• 18.9. Italy
• 18.10. Spain
• 18.11. China
• 18.12. India
• 18.13. Japan
• 18.14. Australia
• 18.15. South Korea

19. Competitive Landscape

• 19.1. Market Concentration Analysis, 2025
  • 19.1.1. Concentration Ratio (CR)
  • 19.1.2. Herfindahl Hirschman Index (HHI)
• 19.2. Recent Developments & Impact Analysis, 2025
• 19.3. Product Portfolio Analysis, 2025
• 19.4. Benchmarking Analysis, 2025

20. Company Profiles

• 20.1. F. Hoffmann-La Roche AG
• 20.2. Novartis AG
• 20.3. Servier Group
• 20.4. Merck & Co. Inc.
• 20.5. Siemens Healthineers AG
• 20.6. Medtronic plc
• 20.7. Bayer AG
• 20.8. Teva Pharmaceutical Industries Ltd.
• 20.9. GE HealthCare Technologies Inc.
• 20.10. Koninklijke Philips N.V.
• 20.11. Laboratory Corporation of America Holdings
• 20.12. Elekta AB
• 20.13. Fujifilm Corporation
• 20.14. Novocure GmbH
• 20.15. Brainlab SE
• 20.16. QIAGEN N.V.
• 20.17. Thermo Fisher Scientific Inc.
• 20.18. Hikma Pharmaceuticals PLC
• 20.19. Sanofi S.A.
• 20.20. Ipsen Pharma
• 20.21. Danaher Corporation
• 20.22. Sun Pharmaceutical Industries Limited
• 20.23. AstraZeneca PLC
• 20.24. Zydus Lifesciences Limited
• 20.25. AbbVie Inc.
• 20.26. Agios Pharmaceuticals, Inc.
• 20.27. Amgen Inc.
• 20.28. Bristol-Myers Squibb Company
• 20.29. Carestream Health, Inc.
• 20.30. Eisai Co., Ltd.
• 20.31. Eli Lilly and Company
• 20.32. GlaxoSmithKline PLC
• 20.33. Illumina, Inc.
• 20.34. Johnson & Johnson Services, Inc.
• 20.35. Karyopharm Therapeutics Inc.
• 20.36. NantOmics
• 20.37. NeoGenomics, Inc.
• 20.38. Oncologica Limited
• 20.39. Perrigo Company
• 20.40. Pfizer Inc.
• 20.41. RemeGen Co., Ltd.
• 20.42. Shimadzu Corporation
• 20.43. Suzhou Puhe BioPharma Co., Ltd.
• 20.44. Takeda Pharmaceutical Company Limited
• 20.45. VBL Therapeutics